B. Metzler Seel. Sohn & Co. Holding Ag Halozyme Therapeutics, Inc. Call Options Transaction History
B. Metzler Seel. Sohn & Co. Holding Ag
- $10.1 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding HALO
# of Institutions
526Shares Held
123MCall Options Held
208KPut Options Held
77.1K-
Black Rock Inc. New York, NY17.6MShares$1.05 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$769 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$347 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$241 Million4.92% of portfolio
-
Alliancebernstein L.P. New York, NY3.55MShares$212 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.3B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...